We were recently made aware of an error in the equation that we used to estimate acetylation stoichiometry in the above‐mentioned article. While this error does not have a major impact on our results or their interpretation, some of the numbers are changed slightly and here we provide updated figures and tables, the equation used, and the revised stoichiometry estimates for individual sites.

To calculate initial stoichiometry (S_{I}), we previously divided the degree of partial chemical acetylation (C) by the SILAC ratio (R) of increased acetylation after partial chemical acetylation, S_{I} = C/R. However, in the correct equation, the SILAC ratio should be subtracted by (1−C), S_{I} = C/(R−(1−C)). This equation was derived as follows. If the final stoichiometry is (S_{F}) = S_{I} + C(1−S_{I}) and the acetylated peptide SILAC ratio (R) = S_{F}/S_{I}, then solving the above equation for S_{I} in terms of S_{F}/S_{I} yields S_{I} = C/((S_{F}/S_{I}) −(1−C)) = C/(R−(1−C)). We determined that C was < 1%, and we estimated stoichiometry using the conservative assumption that C = 1% (0.01); therefore, we previously calculated stoichiometry using the equation S = 0.01/R, while the correct equation is S = 0.01/(R−0.99). We further realized that we could use a previously published equation (Olsen et al, 2010) for calculating stoichiometry and this equation yielded results identical to the revised formula presented above. We now include both equations and the updated stoichiometry estimates in Supplementary Table S9. The new equation had a very small impact on our stoichiometry estimates. Regardless, we have updated Figure 5D and 5H (see below), which were based on our stoichiometry estimates. Most of our other analyses were based on the SILAC ratio after chemical acetylation; therefore, these results were independent of the stoichiometry calculation.

An additional issue is that several of the sites we previously classified as having a high stoichiometry (SILAC ratio L/H < 2) were quantified on doubly acetylated peptides. However, we cannot accurately estimate the degree of partial chemical acetylation at individual sites on doubly acetylated peptides, and for this reason, we could not accurately estimate stoichiometry of acetylation sites occurring on such peptides. In our dataset, doubly acetylated peptides accounted for 20 sites, 14 of which were estimated to have high stoichiometry. These 14 sites included histone H4 (Hhf1) lysines 6, 9, 13, and 17; histone H2AZ (Htz1) lysines 4, 9, and 11; histone H2B (Htb2) lysine 17; Esa1 lysines 6 and 13; Ahc1 lysines 532 and 538; Sgf73 lysine 199; and Snf2 lysine 1494. Sites quantified on doubly acetylated peptides are likely to have a high stoichiometry (the presence of two acetylation sites on the same peptide suggests as much); however, we cannot confidently estimate the stoichiometry of sites that were quantified on these peptides. Sites quantified using doubly acetylated peptides are now indicated in Supplementary Table S9 and we re‐analyzed our data excluding these sites, which resulted in changes to Figure 6A, 6B, and 6D. In addition, to reflect the new analysis excluding sites quantified on doubly acetylated peptides, two portions of the section entitled “Functional analysis of proteins with high stoichiometry acetylation sites” should read as follows (changes are underlined):

– “Half of the AcP‐insensitive sites occurred on histones, proteins present in histone deacetylase (HDAC) or histone acetyltransferase (HAT) complexes, and on transcription factors. We compared the effect of AcP‐treatment on proteins present in different subcellular compartments (Figure 6B). Consistent with GO term analysis, 68% of the high‐stoichiometry, AcP‐insensitive sites occurred on nuclear proteins. In contrast, 97% of mitochondrial and 94% of cytoplasmic acetylation sites were AcP‐sensitive, indicating that the vast majority of acetylation sites in these subcellular compartments were acetylated at a low stoichiometry.”

– “Acetylated sites with high stoichiometry are likely to be important for protein function. Many previously known regulatory acetylation sites were AcP‐insensitive, including Smc3 lysines 112 and 113(Zhang et al, 2008), Sas2 (MYST homolog) lysine 168 (Yuan et al, 2012), Yng2 lysine 170 (Lin et al, 2008), RTT109 lysine 290 (Albaugh et al, 2011b), SNF2 lysine 1498(Kim et al, 2010), histone H2AZ (Htz1) lysine 15 (Babiarz et al, 2006; Lin et al, 2008; Millar et al, 2006), histone H3 (Hht1) lysines 19, 24, and 57 (Hyland et al, 2005; Suka et al, 2001; Zhang et al, 1998), and histone H2B (Htb2) lysines 16. These 11 sites constitute 11% of the 97 AcP‐insensitive sites that we identified, indicating that AcP‐insensitivity is a good predictor of functionally important acetylation sites. The enrichment of functionally characterized sites within the group of AcP‐insensitive sites is highly significant (

*P*= 1e‐11, Fisher exact test).”

The authors apologize for these errors and for any inconvenience caused.

## Supplementary Information

Table S9 [msb156513-sup-0001-TableS9.xlsx]

## Reference

- © 2015 The Authors. Published under the terms of the CC BY 3.0 license